Painreform is trading at $0.81, up +10.94%, with no company-specific announcement identified to explain its after-hours rise on October 30.
- The latest located company update was an October 23 shareholder letter covering cash, a planned Phase 2 trial and GridFeed; it does not establish a cause.
- The broader market was sharply lower, but available evidence does not support attributing the move to market sentiment.
- Trading volume and after-hours activity details were unavailable.